Orexigen Therapeutics
La Jolla
About Orexigen Therapeutics
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its lead combination product candidates include Contrave, which has completed Phase III clinical trials; and Empatic that has completed Phase II clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release formulation (SR). Bupropion is an antidepressant and smoking cessation medication; naltrexone is a treatment for alcohol and opioid addiction. The company's Empatic product candidate is a combination of bupropion SR and zonisamide SR. Zonisamide, in an immediate release formulation for the adjunctive treatment of partial seizures, a form of epilepsy. The company was founded in 2002 and is based in La Jolla, California.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $387.9M
- Funding stage: M&A
- Last round: Post-IPO Equity (Mar 2016)
- Ticker: nasdaq:OREX
- Website: orexigen.com
- Phone: (858) 875-8600
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/orexigen-therapeutics-169748 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.